本文選題：乳腺腫瘤 + 化學(xué)療法療/方法　； 參考：《中國普通外科雜志》2017年05期

【摘要】：目的:探討乳腺癌根治術(shù)后不同時間開始化療對患者臨床預(yù)后的影響。方法:自2012年1月—2013年1月,前瞻性收集我院收治的乳腺癌患者100例,根據(jù)患者術(shù)后化療時間,將患者分為觀察組(開始時間3周)和對照組(開始時間3~8周)。主要觀察指標(biāo)包括臨床療效(無進(jìn)展生存期、生存率和復(fù)發(fā)率)和安全性(治療相關(guān)并發(fā)癥和健康相關(guān)的生存質(zhì)量)。結(jié)果:與對照組相比,觀察組患者無進(jìn)展生存期明顯延長(P=0.049);3年復(fù)發(fā)率明顯降低(20.00%vs.38.00%,P=0.047)。兩組患者生存率無統(tǒng)計學(xué)差異(94.00%vs.92.00%,P=1.000)。觀察組患者術(shù)后1年健康相關(guān)的生存質(zhì)量顯著高于對照組[(73.00±12.16)vs.(64.64±10.58),t=3.677,P=0.000]。兩組患者主要治療相關(guān)并發(fā)癥包括骨髓抑制、貧血、腹瀉、惡心和嘔吐等差異均無統(tǒng)計學(xué)意義(P0.05)。結(jié)論:術(shù)后早期化療有助于延長乳腺癌患者無進(jìn)展生存期,改善患者術(shù)后生存質(zhì)量。
[Abstract]:Objective: to investigate the effect of chemotherapy on the clinical prognosis of patients with breast cancer at different time after radical mastectomy. Methods: from January 2012 to January 2013, 100 patients with breast cancer admitted in our hospital were prospectively collected. According to the time of postoperative chemotherapy, the patients were divided into observation group (starting time 3 weeks) and control group (starting time 3 weeks and 8 weeks). The main outcome measures included clinical efficacy (progression-free survival, survival rate and recurrence rate) and safety (treatment-related complications and health-related quality of life). Results: compared with the control group, the progression-free survival time of the patients in the observation group was significantly longer than that of the control group, and the recurrence rate of 3 years was significantly decreased by 20.00 vs.38.00. There was no statistical difference in survival rate between the two groups. The health-related quality of life in the observation group was significantly higher than that in the control group one year after operation [73.00 鹵10.58 12.16)vs.(64.64 鹵3.677 P0. 000]. There was no significant difference in major treatment-related complications between the two groups, including bone marrow suppression, anemia, diarrhea, nausea and vomiting. Conclusion: early postoperative chemotherapy can prolong the progressive survival of breast cancer patients and improve the postoperative quality of life.
【作者單位】： 浙江省嘉興市第一醫(yī)院乳腺外科;
【分類號】：R737.9
，

本文編號：1907026